AstraZeneca to delist from Nasdaq, join NYSE in February

Core Viewpoint - AstraZeneca will delist its American Depositary Shares and debt securities from Nasdaq and will complete a direct listing of its ordinary shares and debt on the New York Stock Exchange, effective after market close on January 30, 2026 [1] Group 1 - The decision to delist from Nasdaq is part of AstraZeneca's strategy to streamline its listing process [1] - The direct listing on the New York Stock Exchange is expected to enhance the visibility and accessibility of AstraZeneca's shares to investors [1]